Jiangsu HengRui Medicine Co., Ltd.: Prostatic Neoplasms trials
The registry lists 26 Prostatic Neoplasms studies with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor. 11 are open to participants now and 0 have results posted.
Phase 1 19Phase 2 11Phase 3 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Multicenter, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-6914 Injection in Participants With Prostate CancerRecruitingNCT07735377Phase 1
- A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate CancerRecruitingNCT07711184Phase 1
- A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate CancerRecruitingNCT07407283Phase 1/2
- A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate CancerRecruitingNCT07230106Phase 2
- A Study of SHR-4394 Injection in Subjects With Prostate CancerRecruitingNCT06783829Phase 1
- A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and PrednisoneRecruitingNCT06689163Phase 1/2
- A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate CancerRecruitingNCT06568094Phase 1/2
- Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)Not yet recruitingNCT06099990Phase 1
- Phase I Clinical Study of HRS-9815 for PET/CT Imaging in Patients With Prostate CancerNot yet recruitingNCT06062355Phase 1
- Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate CancerNot yet recruitingNCT06006104Phase 1/2
- A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer SubjectsRecruitingNCT05607693Phase 1
- A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral HRS-5041 in Healthy SubjectsCompletedNCT07014488Phase 1
- Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male ParticipantsCompletedNCT06559007Phase 1
- A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate CancerCompletedNCT04995042Phase 1
- A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate CancerCompletedNCT04869488Phase 2
- Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate CancerCompletedNCT04862091Phase 2
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT04691804Phase 3
- The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and OmeprazoleCompletedNCT04676035Phase 1
- Drug-drug Interaction of SHR3680 With Repaglinide and BupropionStatus unknownNCT04664725Phase 1
- A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPCStatus unknownNCT04603833Phase 2
- A Study of Abiraterone in Combination With SHR3162 in the Treatment of mCRPCStatus unknownNCT04108247Phase 1
- A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPCTerminatedNCT04102124Phase 2
- A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPCTerminatedNCT03741712Phase 1/2
- A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate CancerActive, not recruitingNCT03520478Phase 3
- A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate CancerCompletedNCT02747342Phase 1
- A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer PatientsStatus unknownNCT02691975Phase 1/2